Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H23N3O4 |
Molecular Weight | 321.3715 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1
InChI
InChIKey=YKGYIDJEEQRWQH-UHFFFAOYSA-N
InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)
Gabexate is a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role. Gabexate mesylate is a drug marketed only in Italy and Japan and it is considered an essential drug in the treatment of acute pancreatitis. Gabexate is marketed under the brand name REMINARON among others in Japan. It relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation.
It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3051 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9610382 |
5.0 mM [Ki] | ||
Target ID: CHEMBL1075230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9610382 |
0.1 mM [Ki] | ||
Target ID: CHEMBL2319 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9610382 |
2.6 mM [Ki] | ||
Target ID: CHEMBL2000 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | REMINARON Approved UseThis medicine relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation.
It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation. |
|||
Primary | REMINARON Approved UseThis medicine relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation.
It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17351806
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: continuous intravenous infusion (600 mg)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12649382
The LPS-induced increase in TNF-a production by human monocytes was significantly inhibited by gabexate mesilate at a concentration of 1.0 x10(-3) M.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C263
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
||
|
NCI_THESAURUS |
C783
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
||
|
FDA ORPHAN DRUG |
764320
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7863
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
100000084507
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
C76960
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
39492-01-8
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
DB12831
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
3257
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
SUB07858MIG
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
DTXSID9048566
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
3988
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
D016670
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
GABEXATE
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
4V7M9137X9
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
m5620
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | Merck Index | ||
|
3447
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY | |||
|
CHEMBL87563
Created by
admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)